Therapeutic window for calcium-channel blockers in the management of dilated cardiomyopathy: A prospective, two-centre study on non-advanced disease

Cardiology

Volumn 117, Issue 2, 2010, Pages 148-154

  Wojnicz, Romuald ^a,b   Nowak, Jolanta ^b   Lekston, Andrzej ^b   Wilczewski, Przemysław ^b   Nowalany Kozielska, Ewa ^b   Streb, Witold ^a   Wojciechowska, Celina ^b   Stolarz, Wojciech ^b   Helewski, Krzysztof ^b   Szyguła Jurkiewicz, Boena ^b   Poloński, Lech ^a,b  

^a Silesian Centre for Heart Diseases   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Calcium channel blockers; Dilated cardiomyopathy; Heart failure therapy; Verapamil

Indexed keywords

CAPTOPRIL; CARVEDILOL; EPLERENONE; FUROSEMIDE; PERINDOPRIL; SPIRONOLACTONE; VERAPAMIL;

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DEATH; DISEASE COURSE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; FLOW RATE; FUNCTIONAL STATUS; HEART FAILURE; HEART LEFT VENTRICLE FILLING; HEART TRANSPLANTATION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SINUS BRADYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; WALKING;

ADULT; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD FLOW VELOCITY; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; CARDIOMYOPATHY, DILATED; DIASTOLE; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; PROPANOLAMINES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; VERAPAMIL;

EID: 77958138975     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320103     Document Type: Article

References (27)

1. Yusuf S, Sleight P, Pogue J, Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153. (Pubitemid 30051645)
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE study group: Cardiovascular morbidity and mortality in the losartan intervention for endopint reduction in the hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
3. Sonnenblick EH, Fein F, Capasso JM, Factor SM: Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. Am J Cardiol 1985;55:179B-184B.
4. Figulla HR, Vetterlein F, Glaubitz M, Kreuzer H: Inhomogenous capillary flow and its prevention by verapamil and hydralazine in the cardiomyopathic Syrian hamster. Circulation 1987;76:208-216.
5. Factor SM, Cho S, Scheuer J, Sonneblick EH, Malhotra A: Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. J Am Coll Cardiol 1988;12:1599-1604.
6. Dong R, Liu P, Wee L, Butany J, Sole MJ: Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest 1992;90:2022-2030.
7. Elkayam U, Amin J, Mehra A, Vasquez J R N, Weber L R N, Rahimtoda SH: A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic CHF. Circulation 1990;82:1954-1961.
8. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, Prospective Randomized Amlodipine Survival Evoluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
9. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L: Effects of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study group. Circulation 1997;96:856-863.
10. Agostoni PG, De Cesare N, Doria E, Polese A, Tamborini G, Guazzi MD. Afterload reduction: a comparison of captopril and nifrdipine in dilated cardiomyopathy. Br Heart J 1986;55:391-399.
11. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R, DiDi Study Group: Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the diltiazem in dilated cardiomyopathy trial. Circulation 1996;94:346-352.
12. Entman ML, Smith CW: Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994;28:1301-1311.
13. Heuvel A F M, Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink H M J, Vaalburg WM, van Gilst WH, Crijns H J G M: Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2000;35:19-28.
14. Cuspidi C, Sampieri L, Boselli L, Bragato R, Lonati L, Bocciolone M, Leonetti G, Zanchetti A: Cardiac structure and function before and after acute and chronic verapamil administration in hypertensive patients. Cardiology 1991;79:180-187.
15. Marian AJ: Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J 2009;36:194-204.
16. Osadchii OE: Cardiac hypertrophy induced by sustained β-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 2007;12:66-86.
17. Noutsias M, Seeberg B, Schultheiss HP, Kühl U: Expression of cell adhesion molecules in dilated cardiomyopathy. Evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999;99:2124-2131.
18. Yamaguchi M, Suwa H, Miyasaka M, Kumada K: Selective inhibition of vascular cell adhesion molecule-1 expression by verapamil in human vascular endothelial cells. Transplantation 1997;63:759-764.
19. Greene WC, Parker CW: Calcium and lymphocyte activation. Cell Immunol 1976;25:74-89.
20. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R: Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990;66:981-986.
21. Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG: Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994;127:607-612.
22. Naschitz JE, Slobodin G, Lewis RJ, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D: Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J 2000;140:111-120.
23. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos C, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats A: Uric acid and survival in chronic heart failure. Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-1997.
24. Lau GT, Tan HC, Kritharides L: Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol 2002;90:1405-1409.
25. Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, Guererro J, Todd GD, McAllister RG, Gorlin R: Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982;65:660-668.
26. Wenzel RR, Noll G, Lüscher TF: Endothelial regulation of vascular tone and growth: Role of calcium antagonists; in Epstei M (ed): Calcium Antagonists in Clinical Medicine. Philadelphia, Hanley and Belfus, 1998, pp 57-79.
27. Elkayam U: Calcium channel blockers in heart failure. Cardiology 1998;89(suppl 1):38-46.